AlzeCure Pharma AB (publ)

Stockholm Stock Exchange:ALZCUR.ST

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Sweden

Market Cap

USD 25.28 M

Share Price

USD 0.29

Avg Daily Volume

107,200

Change (1 day)

-8.05%

Change (1 year)

Change (YTD)

237.22%

AlzeCure Pharma AB (publ) Revenue for the year ending December 31, 2024: USD 0.00

AlzeCure Pharma AB (publ) Revenue is USD 0.00 for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

AlzeCure Pharma AB (publ) Revenue for the year ending December 31, 2023 was USD 0.00.
AlzeCure Pharma AB (publ) Revenue for the year ending December 31, 2022 was USD 0.00.
AlzeCure Pharma AB (publ) Revenue for the year ending December 31, 2021 was USD 0.00.
AlzeCure Pharma AB (publ) Revenue for the year ending December 31, 2020 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Stockholm Stock Exchange: ALZCUR.ST

AlzeCure Pharma AB (publ)

CEO	Mr. Martin Jönsson
IPO Date	Nov. 28, 2018
Location	Sweden
Headquarters	HAelsovAegen 7
Employees	11
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.